Blood tests for diagnosing and tracking brain diseases and mental disorders
Looks back at blood markers in adults with dementia or mental disorders.
Plain-language title generated from the registry record
Registry title: Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder
Key facts
- Where
- Barcelona, SpainSee the site
Where in Spain
- Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau - IIB Sant PauBarcelona, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Trial code
- NCT07314190
- Record updated
- 23 February 2026
- Original description
This is a retrospective observational study to evaluate the clinical utility of blood-based biomarkers in the diagnosis and management of patients with a neurodegenerative disease (ND) or mental disorder (MD).Read full original descriptionShow less
Synapsing Retrospective Biomarker Study
This is a retrospective observational study to evaluate the clinical utility of blood-based biomarkers in the diagnosis and management of patients with a neurodegenerative disease (ND) or mental disorder (MD).
Inclusion: Age>18 and donation of blood,; full clinical and psychological assessment; Available neuroimaging is optional as not all patients are suitable; Age and sex-matched unaffected volunteers without a MD or ND diagnosis are used as controls; Unaffected controls are usually spouses or children of patients that are informed about our studies at each clinical site.
Exclusion: anticoagulant treatment such as acenocoumarol, heparin, warfarin, dabigatran, rivaroxaban, apixaban, drug abuse in the last year,; the patient has received potentially neurotoxic chemotherapy and/or patient has received cranial radiotherapy; medical history of cancer affecting the central nervous system that has not been in complete remission for 5 years or longer,; Clinical diagnosis of Alzheimer's disease where pathophysiological markers (measured in CSF or plasma) are inconsistent with Alzheimer's disease pathophysiology; Cognitively healthy volunteers where pathophysiological markers (measured in CSF or plasma) are consistent with Alzheimer's disease or other neurodegenerative pathophysiology; Lack of neuropsychological data,.